What does it mean that “Aliqopa” was withdrawn in the Federal Register (March 18, 2024)?
A “withdrawal” in the Federal Register typically refers to the agency rescinding or withdrawing a previously published action (for example, an administrative decision, a proposed rule, or certain regulatory paperwork) from the Federal Register record. Without the specific Federal Register notice text or the docket number, it’s not possible to say which exact Aliqopa-related action was withdrawn on March 18, 2024.
If you paste the link or the Federal Register caption (title of the notice) for the March 18, 2024 entry you mean, I can summarize what was withdrawn and why.
Which agency notice is it—FDA, CMS, or something else?
Aliqopa (copanlisib) is an FDA-regulated cancer drug, so the most common relevant Federal Register items would come from FDA (for example, notices tied to drug approval actions, regulatory procedures, or related administrative steps). But Federal Register entries can also involve other agencies (for example, CMS reimbursement policies) that people loosely associate with a drug name.
To identify the correct notice, look for:
- the Federal Register “AGENCY” line (e.g., FDA)
- the “ACTION” line (e.g., withdrawal, correction)
- the docket number (e.g., FDA-2023-xxxx) or notice number
Can Aliqopa be “withdrawn” from the market, or is this only a Federal Register administrative action?
“Withdrawn” can mean different things depending on the notice:
- An administrative withdrawal of a published notice/action (paperwork or regulatory record).
- A withdrawal tied to a specific approval or determination.
- Less commonly, a drug withdrawal from marketing (which would usually be described in terms like discontinuation or withdrawal of approval/authorization, not just a Federal Register record change).
The exact meaning depends entirely on the notice language for the March 18, 2024 entry.
How to find the exact March 18, 2024 Federal Register notice for Aliqopa
Search the Federal Register for March 18, 2024 and use filters/keywords:
- Keyword: “Aliqopa” (or “copanlisib”)
- Date: March 18, 2024
- Then open the matching entry and capture:
- the full title (caption)
- agency
- docket number
If you share that entry’s text (or link), I’ll extract:
- what action was withdrawn
- effective date
- any stated reason
- what it changes for providers/patients
What do patients and clinicians typically need to know if a Federal Register action references Aliqopa?
When a Federal Register entry is tied to a drug’s regulatory status, the practical impacts usually fall into:
- whether the drug remains approved/available
- whether prescribing, labeling, or use indications change
- whether a prior regulatory step is being undone
But again, the March 18, 2024 notice’s specific content determines the real-world impact.
---
If you paste the Federal Register link or the exact notice caption (or the docket number), I’ll give a precise, plain-English explanation of what the Aliqopa withdrawal was on March 18, 2024 and what it changes.